Federal Register / Vol. 62, No. 162 / Thursday, August 21, 1997 / Notices 44479

Human Services, is publishing the

following summary of proposed

collections for public comment.

Interested persons are invited to send

comments regarding this burden

estimate or any other aspect of this

collection of information, including any

of the following subjects: (1) The

necessity and utility of the proposed

information collection for the proper

performance of the agency’s functions;

(2) the accuracy of the estimated

burden; (3) ways to enhance the quality,

utility, and clarity of the information to

be collected; and (4) the use of

automated collection techniques or

other forms of information technology to

minimize the information collection

burden.

Type of Information Collection

Request: Revision of a currently

approved collection; Title of

Information Collection: Organ

Procurement Organization/

Histocompatibility Laboratory

Statement of Reimbursable Costs,

Manual Instructions and Supporting

Regulations Contained in 42 CFR 413.20

and 413.24; Form No.: HCFA–216 (OMB

No. 0938–0102); Use: This form is

required by statute for participation in

the Medicare program. The information

is used to determine reasonable costs

incurred to furnish treatment to End

Stage Renal Disease (ESRD) patients by

Organ Procurement Organizations and

Histocompatibility Laboratories.

Frequency: Annually; Affected Public:

Business or other for-profit, Not-forprofit institutions, and State, Local or

Tribal Government; Number of

Respondents: 100; Total Annual

Responses: 100; Hours: 4,500.

To obtain copies of the supporting

statement and any related forms for the

proposed paperwork collections

referenced above, E-mail your request,

including your address and phone

number, to Paperwork@hcfa.gov, or call

the Reports Clearance Office on (410)

786–1326. Written comments and

recommendations for the proposed

information collections must be mailed

within 30 days of this notice directly to

the OMB desk officer: OMB Human

Resources and Housing Branch,

Attention: Allison Eydt, New Executive

Office Building, Room 10235,

Washington, D.C. 20503.

Dated: August 14, 1997.

John P. Burke III,

HCFA Reports Clearance Officer, HCFA Office

of Information Services, Information

Technology Investment Management Group,

Division of HCFA Enterprise Standards.

[FR Doc. 97–22199 Filed 8–20–97; 8:45 am]

BILLING CODE 4120–03–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute on Alcohol Abuse

and Alcoholism; Notice of Closed

Meeting

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting:

Purpose/Agenda: To review and evaluate a

request for application (RFA).

Name of Committee: National Institute on

Alcohol Abuse and Alcoholism Special

Emphasis Panel.

Date of Meeting: August 26, 1997.

Time: 8:00 A.M. to adjournment.

Place of Meeting: Radison Barcelo Hotel

2121 P Street, NW, Washington, DC 20037.

Contact Person: Mark Green, 6000

Executive Boulevard, Suite 409, Rockville,

Md 20892–7003, 301–443–2860.

The meeting will be closed in

accordance with the provisions set forth

in sections 552b(c)(4) and 552b(c)(6),

Title 5 U.S.C. The proposal and

discussions could reveal confidential

trade secrets or commercial property

such as patentable material, and

personal information concerning

individuals associated with the

proposal, the disclosure of which would

constitute a clearly unwarranted

invasion of personal privacy.

This notice is being published less

than 15 days prior to the meeting due

to the urgent need to meet timing

limitations imposed by the review and

funding cycle.

(Catalog of Federal Domestic Assistance,

Program Nos. 93.271, Alcohol Research

Career Development Awards for Scientists

and Clinicians; 93.272, Alcohol National

Research Service Awards for Research

Training; 93.273, Alcohol Research Programs;

93.891, Alcohol Research Center Grants;

National Institutes of Health)

Dated: August 13, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–22162 Filed 8–20–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute on Drug Abuse;

Notice of Closed Meetings

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

National Institute on Drug Abuse

(NIDA) Special Emphasis Panel

meetings:

Purpose/Agenda: To evaluate and review

contract proposals.

Name of Committee: NIDA Special

Emphasis Panel (Controlled Release

Parenteral Delivery System of

Buprenorphine).

Date: August 18, 1997.

Time: 1:30 p.m.

Place: Office of Extramural Program

Review, National Institute on Drug Abuse,

NIH, 5600 Fishers Lane, Room 10–49,

Rockville, MD 20857 (Telephone

Conference).

Contact Person: Mr. Eric Zatman, Contract

Review Specialist, Office of Extramural

Program Review, National Institute on Drug

Abuse, 5600 Fishers Lane, Room 10–42,

Rockville, MD 20857, Telephone (301) 443–

1644.

Name of Committee: NIDA Special

Emphasis Panel (Preparation of Standardized

Nicotine and Cigarettes for Addiction).

Date: August 18, 1997.

Time: 2:30 p.m.

Place: Office of Extramural Program

Review, National Institute on Drug Abuse,

NIH, 5600 Fishers Lane, Room 10–49,

Rockville, MD 20857 (Telephone

Conference).

Contact Person: Mr. Eric Zatman, Contract

Review Specialist, Office of Extramural

Program Review, National Institute on Drug

Abuse, 5600 Fishers Lane, Room 10–42,

Rockville, MD 20857, Telephone (301) 443–

1644.

This notice is being published less

than 15 days prior to the meetings due

to the urgent need to meet timing

limitations imposed by the review and

funding cycle.

The meetings will be closed in

accordance with provisions set forth in

sections 552b(c)(4) and 552b(c)(6), Title

5, U.S.C. The applications and/or

proposals and the discussions could

reveal confidential trade secrets or

commercial property such as patentable

material and personal information

concerning individuals associated with

the applications and/or proposals, the

disclosure of which would constitute a

clearly unwarranted invasion of

personal privacy.

(Catalog of Federal Domestic Assistance

Program Numbers: 93.277, Drug Abuse

Scientist Development, Research Scientist

Development, and Research Scientist

Awards; 93.278, Drug Abuse National

Research Service Awards for Research

Training; 93.279, Drug Abuse Research

Programs, National Institutes of Health)

Dated: August 13, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–22164 Filed 8–20–97; 8:45 am]

BILLING CODE 4140–01–M